Alyacen 1/35 Shortage: What Providers and Prescribers Need to Know in 2026

Patients are increasingly arriving at appointments frustrated that they cannot fill Alyacen 1/35 at their local pharmacy. While Alyacen 1/35 does not appear on the FDA's official drug shortage list as of 2026, its status as a limited-distribution branded generic from a single manufacturer (Glenmark Pharmaceuticals) means localized stocking gaps are a persistent reality. This guide is designed to help OB/GYNs, primary care physicians, nurse practitioners, and physician assistants navigate these situations efficiently and keep patients protected.

Current Availability Status (2026)

Alyacen 1/35 (norethindrone 1 mg / ethinyl estradiol 0.035 mg) is not on the FDA drug shortage database as of early 2026. However, several pharmacy platforms and wholesaler tracking services classify it as having limited distribution — meaning it is not universally stocked across retail pharmacy networks. Patients in certain regions, particularly those relying on smaller independent pharmacies or pharmacies with narrow formulary agreements, may have difficulty filling this prescription on demand.

Why This Matters Clinically

Oral contraceptive efficacy depends critically on consistent, uninterrupted use. A gap of as few as 2-3 missed active pills in certain cycle windows can meaningfully compromise contraceptive protection. Beyond pregnancy prevention, many patients use Alyacen 1/35 off-label for dysmenorrhea, endometriosis management, PCOS cycle regulation, and acne — conditions that can flare rapidly when hormonal therapy is interrupted.

Bioequivalent Substitutes: Clinically Appropriate Options

The following medications are FDA AB-rated bioequivalents of Alyacen 1/35, containing identical active ingredients (norethindrone 1 mg / ethinyl estradiol 0.035 mg). For patients who are stable on Alyacen 1/35, switching to any of these is clinically appropriate without the need for a new prescription in most states:

• Nortrel 1/35 — most widely distributed alternative; often available where Alyacen is not.

• Dasetta 1/35 — AB-rated; same hormonal profile and dosing schedule.

• Pirmella 1/35, Cyclafem 1/35, Nylia 1/35 — additional AB-rated alternatives, broadening pharmacy search options.

All of these are monophasic formulations with the same 28-day cycle structure (21 active + 7 inert tablets). Patients will not experience a change in cycle control or contraceptive efficacy when switching between AB-rated bioequivalents. Minor differences in inactive ingredient profiles (fillers, dyes) are unlikely to be clinically significant.

When to Consider a Different Formulation

If bioequivalent substitution is not possible or the patient has uncontrolled side effects on norethindrone/EE, consider the following alternatives based on clinical context:

• Norgestimate/EE (Sprintec, Ortho-Cyclen equivalents): First-generation progestin with favorable lipid profile. Widely available and low cost. Good for patients tolerating the estrogen component well.

• Drospirenone/EE (Yaz, Loryna): Anti-androgenic progestin; indicated for PMDD and acne. Slightly higher VTE risk; not appropriate for patients with renal or hepatic impairment or potassium retention concerns.

• Progestin-only pill (norethindrone 0.35 mg, e.g., Camila, Jolivette): Appropriate if patient has contraindications to estrogen (migraines with aura, VTE history, smoking >35, postpartum/breastfeeding).

• Long-acting reversible contraception (Nexplanon, IUD): Consider for patients who have struggled repeatedly with pill access — LARC eliminates the refill problem entirely.

Prescribing Strategies to Minimize Patient Disruption

Several prescribing practices can help reduce the risk of patients experiencing gaps:

• Prescribe a 90-day supply whenever possible. This reduces refill frequency and provides a larger buffer against supply gaps. Most insurance plans allow 90-day fills for maintenance medications including oral contraceptives.

• Write DAW-0 (dispense as written off / substitution permitted). Unless there's a clinical reason to require Alyacen 1/35 specifically, allow substitution so pharmacists can use available AB-rated alternatives without needing to contact you.

• Maintain a short list of preferred formulary alternatives. Be ready to call in a prescription for Nortrel 1/35 or another bioequivalent quickly when a patient calls your office reporting a fill problem.

• Counsel patients on emergency contraception. If a patient cannot fill their prescription in time and has had unprotected intercourse, ensure they know about OTC levonorgestrel (Plan B) as a backup.

Communicating Effectively With Patients About Supply Issues

Patients may feel anxious or confused when told their exact pill isn't available. Reassure them with clear, specific language:

• Explain that Nortrel 1/35 and other substitutes are not "different drugs" — they're the same hormones at the same dose.

• Confirm that switching brands mid-pack is acceptable in this case — they can start the new brand the day after their last active pill of the current pack.

• Recommend medfinder (medfinder.com/providers) as a resource — a paid service that contacts local pharmacies on the patient's behalf to find which ones have their medication.

Key Takeaways for Prescribers

• Alyacen 1/35 is not on the FDA shortage list but has limited distribution at some pharmacies.

• Nortrel 1/35, Dasetta 1/35, and Pirmella 1/35 are AB-rated bioequivalents with identical active ingredients.

• Prescribing 90-day supplies and allowing substitution reduces the frequency of patient access problems.

• For patients with recurrent access issues, consider counseling about LARC as a long-term solution.

For a comprehensive prescriber toolkit, see our guide on how to help your patients find Alyacen 1/35. You can also direct patients to medfinder for providers for a pharmacy location service.